A Clinical Evaluation of the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries.

Trial Profile

A Clinical Evaluation of the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2015

At a glance

  • Drugs Zotarolimus (Primary)
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ENDEAVOR-SVS
  • Sponsors Medtronic
  • Most Recent Events

    • 07 Jun 2011 Planned end date changed from 1 Nov 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
    • 08 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 19 Aug 2010 Planned end date changed from 1 Jul 2009 to 1 Nov 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top